ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CURX vs UPC // FORWARD P/E MULTIPLE

Curanex Pharmaceuticals Inc (NASDAQ) VS. Universe Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: CURX 2 — UPC 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CURX VS. UPC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CURX UPC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 35.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -16.30% — TIE /operating-margins <GO>
Net Profit Margin — -20.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — -22.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 UPC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 23.3 +28.60 CURX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.7M $7.7M $9.6K CURX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CURX REV UPC REV CURX GROSS % UPC GROSS % CURX FCF UPC FCF
FY 2025 $0 $17.86B — 35.3% -$10.5M -$5.32B
FY 2024 $0 $23.02B — 26.4% -$555.6K -$9.72B
FY 2023 — $32.31B — — — $1.12B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CURX // BETA —
UPC // BETA —